|
14 Sep 2025 |
Jyothy Labs
|
Consensus Share Price Target
|
325.20 |
399.38 |
- |
22.81 |
buy
|
|
|
|
|
01 Feb 2024
|
Jyothy Labs
|
Axis Direct
|
325.20
|
565.00
|
508.20
(-36.01%)
|
Target met |
Buy
|
|
|
With a 10% upside from the CMP, we maintain our long-term BUY rating on the stock.
|
|
16 Nov 2023
|
Jyothy Labs
|
Geojit BNP Paribas
|
325.20
|
405.00
|
439.20
(-25.96%)
|
Target met |
Sell
|
|
|
|
|
08 Nov 2023
|
Jyothy Labs
|
Axis Direct
|
325.20
|
450.00
|
416.50
(-21.92%)
|
Target met |
Buy
|
|
|
With a 12% upside from the CMP we maintain our long-term BUY rating on the stock.
|
|
08 Nov 2023
|
Jyothy Labs
|
ICICI Securities Limited
|
325.20
|
465.00
|
401.40
(-18.98%)
|
Target met |
Buy
|
|
|
In this analyst's 15-year sell-side career, he has witnessed many [deserving and momentum-based] rerating and derating stories. We reckon, JYL stock will continue to rerate as it reaps the gains of focused strategy and improved execution under Ms Jyothy's leadership.
|
|
07 Nov 2023
|
Jyothy Labs
|
Motilal Oswal
|
325.20
|
391.00
|
401.40
(-18.98%)
|
Target met |
Neutral
|
|
|
|
|
23 Oct 2023
|
Jyothy Labs
|
Axis Direct
|
325.20
|
440.00
|
350.95
(-7.34%)
|
Target met |
Buy
|
|
|
we initiate coverage on Jyothy Labs Ltd with a resounding "BUY" rating. We value the company at 35x Sep-25 EPS, arriving at a Target Price of Rs 440/Share. This suggests a substantial upside of 20% from the current market price.
|
|
21 Sep 2023
|
Jyothy Labs
|
Motilal Oswal
|
325.20
|
345.00
|
351.00
(-7.35%)
|
Target met |
Neutral
|
|
|
|
|
24 Aug 2023
|
Jyothy Labs
|
Sharekhan
|
325.20
|
375.00
|
337.00
(-3.50%)
|
Target met |
Buy
|
|
|
|
|
07 Aug 2023
|
Jyothy Labs
|
Geojit BNP Paribas
|
325.20
|
291.00
|
319.75
(1.70%)
|
|
Sell
|
|
|
|
|
26 Jul 2023
|
Jyothy Labs
|
ICICI Securities Limited
|
325.20
|
340.00
|
290.90
(11.79%)
|
Target met |
Buy
|
|
|
We are repeating the headline used previously about JYL's performance. Our conviction is intact. Its performance continues to be impressive under Ms Jyothy's leadership. 1QFY24 underlying results stay good and improving – (1) +15% revenue growth YoY (+9% YoY volume growth) and (2) focus on laying (medium-term) building blocks – rural & LUP focus along with distribution expansion. The good performance was across segments led by Personal care and Fabric Care.
|